InvestorsHub Logo
Followers 229
Posts 21458
Boards Moderated 2
Alias Born 08/03/2006

Re: makinezmoney post# 1895

Tuesday, 11/30/2021 6:11:15 PM

Tuesday, November 30, 2021 6:11:15 PM

Post# of 2139
Robert Foster, PharmD, PhD, Hepion’s CEO, added, “This Fast Track designation provides for early and frequent communication with the FDA that will continue throughout the drug development and review process, which may lead to a more expedited drug approval and patient access to CRV431. Additionally, as part of the FDA Fast Track designation for CRV431 in NASH, Hepion will make its expanded access policy publicly available in the coming weeks.”

Just getting started.


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News